Navigation Links
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Date:6/10/2013

EMERYVILLE, Calif., June 10, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin; amantadine HCl extended release) met the study's primary endpoint.  ADS-5102 is an investigational extended-release formulation of amantadine intended for once-nightly administration that is being evaluated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. 

"I am pleased to report our Phase 2/3 EASED study of ADS-5102 for the treatment of LID in Parkinson's disease met the study's primary endpoint with statistical significance," said Gregory T. Went, Ph.D., Chief Executive Officer of Adamas.  "We look forward to sharing the clinical results from the EASED trial of ADS-5102 at the upcoming International Congress of Parkinson's Disease and Movement Disorders."  

Data from the Phase 2/3 EASED clinical study of ADS-5102 have been accepted for presentation at the 17th International Congress of Parkinson's Disease and Movement Disorders taking place on June 16-20, 2013 in Sydney, Australia.  Rajesh Pahwa, M.D., Professor of Neurology, University of Kansas Medical Center and an investigator for the EASED study will present the final results during the "Parkinson's Disease: Clinical Trials" session in a poster entitled Randomized Trial of Extended Release Amantadine in Parkinson's Disease Patients with Levodopa-induced Dyskinesia (EASED Study) (abstract #443) on June 18, 2013 at 12:30 pm AEST.

About the EASED Study
The EASED study was a randomized, double-blind, placebo-controlled clinical trial that enrolled 83 Parkinson
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
3. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
9. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... 25, 2014 Thousands of transvaginal mesh ... in a number of multidistrict litigations currently underway in ... Liebhard LLP reports. According to an Order issued on ... a Joint Status Conference in all of the proceedings ... been directed to submit a proposed agenda to the ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 AlignLife of ... unable to afford certain items. During the holiday season, AlignLife ... collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of ... staff such joy, knowing that we are able to give ... had it not been for the generosity of our patients." ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
... News) -- Most head and neck cancer patients can ... treatment, but several factors may be associated with poor ... patients who were assessed nearly three years after they ... neck cancer. The U.S. researchers gave a speaking ...
... to develop genital cancer, especially as they grow older. ... sexes suffer from the condition, which is extremely difficult to ... of the similarity of the disease to human genital cancer ... Several human genital cancers, including cervical tumours, are known ...
... Nasal congestion can be a sign of severe asthma, ... when it comes to nasal complaints. Furthermore, more severe ... reveals a study from the Sahlgrenska Academy,s Krefting Research ... Respiratory Research , the population study included 30,000 randomly ...
... the effects of monensin emerged in a project investigating ... the growth of prostate cancer cells. The project involved ... found that small amounts of compounds disulfiram (Antabus), ... growth of prostate cancer cells without significant effects on ...
... The hectic pace of the holiday season can make it ... conditions to maintain normal routines and medication schedules. This can ... errors, according to the American Pain Foundation. But a ... over the holidays, the foundation says. If you,re traveling, ...
Cached Medicine News:Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2Health News:A possible cause -- and cure -- for genital cancer in horses? 2Health News:Nasal congestion can mean severe asthma 2Health News:Finnish researchers find a compound that prevents the growth of prostate cancer cells 2Health News:Hectic Holiday Pace Can Upset Medication Schedule 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: